Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA1 | P00915 | 1/20 | 0.40 |
| ▸ | CA2 | P00918 | 1/20 | 0.40 |
| ▸ | HTT | P42858 | 1/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.37 |
| ▸ | GAA | P10253 | 1/20 | 0.37 |
| ▸ | MAPT | P10636 | 1/20 | 0.37 |
| ▸ | PNMT | P11086 | 1/20 | 0.36 |
| ▸ | IMPDH2 | P12268 | 3/20 | 0.35 |
| ▸ | IMPDH1 | P20839 | 2/20 | 0.35 |
| ▸ | TSHR | P16473 | 1/20 | 0.34 |
| ▸ | DYRK1A | Q13627 | 3/20 | 0.34 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.33 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.33 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.33 |
| ▸ | AR | P10275 | 1/20 | 0.33 |
| ▸ | SLC9A1 | P19634 | 1/20 | 0.32 |
| ▸ | LMNA | P02545 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL250481 | 0.86 | IMPDH2 (0.40) | CA1CA2HTTKDM4EALDH1A1 | |
| SCHEMBL28731531 | 0.80 | FABP7 (0.32) | — | |
| SCHEMBL7306217 | 0.77 | AR (0.36) | CA1CA2KDM4EALDH1A1GAA | |
| SCHEMBL21858034 | 0.77 | CHAT (0.50) | CA1CA2HTTKDM4EALDH1A1 | |
| SCHEMBL5746900 | 0.77 | HTT (0.40) | CA1CA2HTTKDM4EALDH1A1 | |
| SCHEMBL5751561 | 0.77 | HTT (0.40) | CA1CA2HTTKDM4EALDH1A1 | |
| SCHEMBL21858110 | 0.76 | CHAT (0.45) | CA2HTTKDM4EALDH1A1MAPT | |
| SCHEMBL29489124 | 0.75 | CA1 (0.54) | CA1CA2HTTKDM4EALDH1A1 | |
| SCHEMBL45954 | 0.75 | CA1 (0.54) | CA1CA2HTTKDM4EALDH1A1 | |
| SCHEMBL7299420 | 0.72 | CA1 (0.40) | CA1CA2HTTKDM4EALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 39 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3749631-B1 | TRIARYLMETHANE COMPOUNDS | MITSUBISHI GAS CHEMICAL CO (JP) | 2024-03-06 | — | — | EP | claimed |
| US-20230391704-A1 | TRIARYLMETHANE COMPOUNDS | MITSUBISHI GAS CHEMICAL COMPANY, INC. (JP) | 2023-12-07 | — | — | US | claimed |
| US-20210371367-A1 | TRIARYLMETHANE COMPOUNDS | MITSUBISHI GAS CHEMICAL COMPANY, INC. (JP) | 2021-12-02 | — | — | US | claimed |
| US-4125619-A | ANTITHROMBOSIS | MITSUBISHI CHEMICAL INDUSTRIES, LTD. (JP) | 1978-11-14 | — | — | US | claimed |
| US-4049645-A | ANTITHROMBOTIC AGENTS | MITSUBISHI CHEMICAL INDUSTRIES LIMITED (JA) | 1977-09-20 | — | — | US | claimed |
| EP-3749631-B1 | TRIARYLMETHANE COMPOUNDS | MITSUBISHI GAS CHEMICAL CO (JP) | 2024-03-06 | — | — | EP | disclosed |
| US-20230391704-A1 | TRIARYLMETHANE COMPOUNDS | MITSUBISHI GAS CHEMICAL COMPANY, INC. (JP) | 2023-12-07 | — | — | US | disclosed |
| CN-111094223-B | binaphthyl compounds | 罗伊特化学仪器制造公司 | 2023-10-27 | — | — | CN | disclosed |
| US-11760712-B2 | Triarylmethane compounds | MITSUBISHI GAS CHEMICAL COMPANY, INC. (JP) | 2023-09-19 | — | — | US | disclosed |
| US-20210371367-A1 | TRIARYLMETHANE COMPOUNDS | MITSUBISHI GAS CHEMICAL COMPANY, INC. (JP) | 2021-12-02 | — | — | US | disclosed |
| US-11072573-B2 | Binaphthyl compounds | REUTER CHEMISCHE APPARATEBAU E.K. (DE) | 2021-07-27 | — | — | US | disclosed |
| EP-3749631-A1 | TRIARYLMETHANE COMPOUNDS | MITSUBISHI GAS CHEMICAL COMPANY, INC. (JP) | 2020-12-16 | — | — | EP | disclosed |
| US-20060178375-A1 | Heteroaryloxy nitrogenous saturated heterocyclic derivative | MSD K.K. (JP) | 2006-08-10 | — | — | US | disclosed |
| EP-1669390-A1 | POLYAMINOPYRIDINES AND METHOD FOR PRODUCING SAME | SUMITOMO SEIKA CHEMICALS CO., LTD. (JP) | 2006-06-14 | — | — | EP | disclosed |
| EP-1642898-A1 | HETEROARYLOXY NITROGENOUS SATURATED HETEROCYCLIC DERIVATIVE | BANYU PHARMACEUTICAL CO., LTD. (JP) | 2006-04-05 | — | — | EP | disclosed |
| US-20050004227-A1 | Cell growth inhibitor | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2005-01-06 | — | — | US | disclosed |
| EP-1437142-A1 | CELL GROWTH INHIBITORS | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2004-07-14 | — | — | EP | disclosed |
| EP-0733626-B1 | N-(Benzofuranazyl)-arylsulphonamides and their analogues useful as endothelin-receptor-antagonists | MERCK PATENT GMBH (DE) | 1999-01-13 | — | — | EP | disclosed |
| US-5726194-A | Endothelin receptor antagonists | MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) | 1998-03-10 | — | — | US | disclosed |
| EP-0733626-A1 | N-(Benzofuranazyl)-arylsulphonamides and their analogues useful as endothelin-receptor-antagonists | MERCK PATENT GmbH (DE) | 1996-09-25 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230391704-A1 | TRIARYLMETHANE COMPOUNDS | CBR3, HAX1, HRH3 | CA1 3881/4885CA2 3417/4885HTT 574/4885 |
| US-20050004227-A1 | Cell growth inhibitor | METAP1, SLC7A1, SLC75A1 | CA1 1006/4885CA2 837/4885HTT 4364/4885 |
| US-11760712-B2 | Triarylmethane compounds | CBR3, HAX1, HRH3 | CA1 3881/4885CA2 3417/4885HTT 574/4885 |
| US-20210371367-A1 | TRIARYLMETHANE COMPOUNDS | CBR3, HAX1, HRH3 | CA1 3881/4885CA2 3417/4885HTT 574/4885 |
| US-20060178375-A1 | Heteroaryloxy nitrogenous saturated heterocyclic derivative | HRH3, HRH4, HCRTR2 | CA1 1810/4885CA2 756/4885HTT 799/4885 |
| US-11072573-B2 | Binaphthyl compounds | UACA, C9, C1S | CA1 2130/4885CA2 1813/4885HTT 1022/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.